key: cord-1010636-e1ezav3h
authors: Ji, Pan; Zhu, Jieyun; Zhong, Zhimei; Li, Hongyuan; Pang, Jielong; Li, Bocheng; Zhang, Jianfeng
title: Association of elevated inflammatory markers and severe COVID-19: A meta-analysis
date: 2020-11-20
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000023315
sha: 4588c43114361abd9d83a3902f1031af24d7af05
doc_id: 1010636
cord_uid: e1ezav3h

Our study aimed to assess the existing evidence on whether severe coronavirus disease 2019 (COVID-19) is associated with elevated inflammatory markers. The PubMed, Embase, Web of Science, Scopus, Chinese National Knowledge Infrastructure, WanFang, and China Science and Technology Journal databases were searched to identify studies published between January 1 and April 21, 2020 that assayed inflammatory markers in COVID-19 patients. Three reviewers independently examined the literature, extracted relevant data, and assessed the risk of publication bias before including the meta-analysis studies. Fifty-six studies involving 8719 COVID-19 patients were identified. Meta-analysis showed that patients with severe disease showed elevated levels of white blood cell count (WMD: 1.15, 95% CI: 0.78–1.52), C-reactive protein (WMD: 38.85, 95% CI: 31.19–46.52), procalcitonin (WMD: 0.08, 95% CI: 0.06–0.11), erythrocyte sedimentation rate (WMD: 10.15, 95% CI: 5.03–15.46), interleukin-6 (WMD: 23.87, 95% CI: 15.95–31.78), and interleukin-10 (WMD: 2.12, 95% CI: 1.97–2.28). Similarly, COVID-19 patients who died during follow-up showed significantly higher levels of white blood cell count (WMD: 4.11, 95% CI: 3.25–4.97), C-reactive protein (WMD: 74.18, 95% CI: 56.63–91.73), procalcitonin (WMD: 0.26, 95% CI: 0.11–0.42), erythrocyte sedimentation rate (WMD: 10.94, 95% CI: 4.79–17.09), and interleukin-6 (WMD: 59.88, 95% CI: 19.46–100.30) than survivors. Severe COVID-19 is associated with higher levels of inflammatory markers than a mild disease, so tracking these markers may allow early identification or even prediction of disease progression.

The outbreak of coronavirus disease 2019 in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a severe threat to global public health. Data from the World Health Organization indicate that as of April 26, 2020, there were more than 2 million confirmed COVID-19 infections and nearly 200,000 COVID-19 deaths in 208 countries or territories. [1] The number of new cases continues to rise rapidly worldwide, which poses a significant challenge to public health. [1] While the disease is mild or even asymptomatic in most patients, and usually self-resolves without the need for hospitalization, it can rapidly and unpredictably progress to a severe form requiring hospitalization and intensive care.

Single-center studies suggest that numerous inflammation markers are elevated in patients in the intensive care unit [2] or patients with severe disease [3] [4] [5] relative to patients with milder conditions. These markers include leukocyte count, procalcitonin level (PCT), C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-10 (IL-10). A meta-analysis also suggested that patients with increased PCT are nearly 5-fold more likely to have severe infection. [6] Although several studies have suggested that severe disease may be associated with elevated WBC count, CRP, PCT, and IL-6, [5, [7] [8] [9] the results across these studies are not entirely consistent. So far, it is unclear whether inflammatory markers are significantly higher in patients with severe COVID-19 than in those with mild disease. Therefore, to gain a clearer picture of the potential association between inflammatory markers and severe COVID-19, we meta-analyzed the relevant literature. The results may provide a basis for detecting or even predicting disease progression quickly enough to improve prognosis.

According to the Preferred Reporting Items for Meta-Analyses of Observational Studies in Epidemiology Statement, [10] our metaanalysis was carried out. We selected relevant studies published between January 1, 2020 and April 21, 2020. The literature was systematically searched using 7 databases: PubMed, Embase, Web of Science, Scopus, Chinese National Knowledge Infrastructure, WanFang, and the China Science and Technology Journal Database. Only literature available online was included, and no language restriction was imposed. The following keywords were used, both separately and in combination, when searching each database: "Coronavirus,""2019-nCoV," "COVID-19," "SARS-CoV-2," "IL-6," "IL-8," "IL-10," "tumor necrosis factor-alpha (TNF-a)," "erythrocyte sedimentation rate (ESR)," "procalcitonin," "C-reactive protein," "ESR," or "Laboratory finding."

A study was included in the meta-analysis if it had a cohort, casecontrol, or case series design involving more than 20 patients with confirmed COVID-19; if it contained patients with the mild, jj Score based on the Newcastle-Ottawa Scale guidelines. [11] Ji et al. Medicine (2020) 

Three reviewers independently screened the articles' titles and abstract to assess whether they were eligible for inclusion. The following data were extracted from included studies into an Excel database: the first author's surname, the publication date of the article, study design, sample size, age, outcome indicators, and assessment of bias risk. A fourth reviewer resolved disagreements. When necessary, authors of the original studies were contacted to obtain further information or clarification. The quality of included studies was assessed based on the Newcastle-Ottawa Scale guidelines. [11] Three reviewers assessed study quality, and differences were resolved through discussion. Studies scoring more than 6 out of the total possible 9 points were considered high quality.

For studies that reported continuous data as ranges or as medians and interquartile ranges, the means and standard deviation were calculated as described. [12] All meta-analyses were performed using STATA 12 (StataCorp, TX) and a significance definition of 2-tailed P < .05. We calculated the weighted mean difference (WMD) and 95% confidence interval (CI) for differences in continuous variables between patients with severe or mild COVID-19 and between all COVID-19 patients who survived or died follow-up. Heterogeneity between studies was analyzed using the x 2 test with significance set at P < .10 and was quantified using the I 2 statistic. The fixed-effect model was utilized when there was no significant heterogeneity in the pooled data. Otherwise, a sensitivity analysis was used to identify the study or studies explaining most of the heterogeneity, then these studies were removed, and the remaining ones were metaanalyzed using a random-effects model. Publication bias was 

A total of 1417 records were identified from the various databases examined, and 35 additional records were identified from the Chinese Medical Journal Network. After a detailed assessment based on the inclusion criteria, 56 studies [2] [3] [4] [5] 8, 9, involving 8719 COVID-19 patients were included in the metaanalysis (Fig. 1) .

All studies included in the meta-analysis were conducted in China and published between February 6, 2020 and April 21, 2020. These retrospective studies examined Chinese patients distributed across 31 provinces. Follow-up data were reported for most patients. All studies received quality scores varying from 6 to 9 points, indicating high quality (Table 1) . Table 2 ). In contrast, the 2 groups showed similar TNF-a levels.

Eight studies [16] [17] [18] [19] 48, 54, 56, 61] comparing 543 COVID-19 patients who died during follow-up with 1713 who remained alive during the same period found that on admission, patients who subsequently died showed significantly higher white blood cell count (WMD Table 2 ).

For most of the outcomes described in Section 3.3.1, there was heterogeneity in the pooled data, with I 2 ranging from 60.1% to 98.5%. Therefore we repeated each meta-analysis after excluding 1 study at a time. We found that the results did not change substantially (Fig. 6) , suggesting our original meta-analyses' reliability.

Inflammation markers can appear elevated in infected individuals, including those infected with SARS-CoV-2. [54] Previous work suggested that the magnitude of the elevation WBC count, CRP, PCT, and IL-6 may relate to the severity of the resulting COVID-19. [17, 59] The National Health Commission of the People's Republic of China included elevated inflammatory factors such as IL-6 and CRP as potential early warning indicators of severe disease in its widely used "COVID-19 diagnosis and treatment plan (for version 7)." [63] While these considerations imply that monitoring levels of inflammatory markers may help identify progression to severe disease, the literature has not been entirely consistent on which markers may be useful in this regard. For example, at least 2 studies found white blood cell count is similar or even lower in severe disease than in mild disease [23, 44] in severe disease, yet other studies found the same marker to be higher in severe disease. [32, 35] To help clarify the inflammatory markers whose elevation may signal severe COVID-19, we meta-analyzed the relevant literature from January 1, 2020, at the beginning of what would quickly become a global pandemic. Our analysis of 56 studies [2] [3] [4] [5] 8, 9, involving 8719 patients with confirmed COVID-19 suggests that WBC, CRP, PCT, ESR, and IL-6 are significantly higher with mild disease, and higher in those who die during follow-up than in those who survive. It is also noteworthy that our results are also in keeping with those of previous studies, [6, 64, 65] but our study included larger sample size and the analyzed inflammation markers that are more comprehensive. However, there is no insufficient evidence that shows a ranking Our results are consistent with the idea that IL-6 levels positively correlate with COVID-19 severity, [38] with levels in critically ill patients exceeding those with the milder disease by up to 10 times. [38] Our results are also consistent with a positive correlation between IL-6 levels and the risk of mortality. [57] IL-6 has strong pro-inflammatory effects. [66] [67] [68] Increases in IL-6 also trigger increases in PCT, which may explain why both are significantly higher in severe COVID-19. [69] The reason for there is no significant difference in TNF-a levels between mild and severe groups is unclear, but it may be related to the inhibition of .004 CI = confidence interval, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, IL-10 = interleukin-10, IL-6 = interleukin-6, PCT = procalcitonin, TNF-a = tumor necrosis factor-a, WBC = white blood cell count, WMD = weighted mean difference. * R means random model; F means fixed model. Th2 cells involved in humoral immunity in the early stage of infection [3] or the sample size is small, and the results are not representative. The increase in inflammatory markers seen with severe COVID-19 is reminiscent of increases in similar markers during infection. For example, upon bacterial infection, PCT is released into the circulation, and elevated levels in peripheral blood correlate with infection severity. [5] Tan et al [70] found that CRP increased significantly in the initial stage of severe COVID-19 infection, while there was no significant difference in CT imaging between the severe group and the mild group. Research is needed to clarify to what extent the increases in inflammatory markers are caused directly by SARS-CoV-2 or reflect comorbidities such as hypertension, diabetes mellitus, and other chronic diseases that, like infectious diseases, trigger a chronic proinflammatory state. Patients with such comorbidities are more likely to develop severe COVID-19 than patients who are otherwise healthy, [71] at least partly because such conditions weaken the innate immune response, increasing the risk of SARS-CoV-2 infection. [70] Our results suggest that monitoring inflammatory markers may serve as an early warning system for progression to severe COVID-19. Simultaneously, monitoring levels of IL-6, CRP, and PCT can allow early detection of bacterial infections, which may reduce overprescription of antibiotics for patients who do not need them and trigger early antibiotic therapy to prevent sepsis and other severe conditions. [72] Although our meta-analysis rigorously analyzed data from a large sample of COVID-19 patients, our results are limited by the heterogeneity observed across studies, such as in the disease course and severity, reflecting the difficulties of standardizing methods during an emerging epidemic. We could not control for these and other potential confounders because all studies in our meta-analysis were retrospective. Due to the nature of reporting in the emerging outbreak, we did not perform a risk of bias assessment and presume it to be high across studies, which should be considered when interpreting results.

In summary, current evidence showed that higher levels of inflammatory markers such as WBC, CRP, PCT, ESR, IL-6, and IL-10 are associated with the severity of COVID-19 and thus could be used as significant prognostic factors of the disease.

Zhimei Zhong, Hongyuan Li, Jielong Pang, and Bocheng Li collected and analyzed the data. Jianfeng Zhang acquired the funding. Pan Ji and Jieyun Zhu designed the study and wrote the first draft of the manuscript. Jianfeng Zhang designed and supervised the study, and finalized the manuscript, which all authors read and approved. 

COVID-19) Situation Dashboard

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical features of coronavirus disease 2019 in Northeast area of Chongqing: analysis of 143 cases

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

Interleukin-6 as a potential biomarker of COVID-19 progression

Clinical characteristics of 223 novel coronavirus pneumonia cases in Chongqing

Clinical characteristics and treatment analysis of 79 cases of COVID-19

Meta-analysis of observational studies in epidemiology: a proposal for reporting

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Estimating the mean and variance from the median, range, and the size of a sample

The correlation between acute phase protein combined biochemical indicators and clinical classification of COVID-19

Expressions of multiple inflammation markers in the patients with 2019 novel coronavirus pneumonia and their clinical values

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan China: a retrospective cohort study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and outcomes of 344 intensive care patients with COVID-19

Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019

Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia

The clinical characteristics and outcome of 62 patients with COVID-19

Clinical characteristics of 2019 novel corona virus infection in China

Epidemiologic and clinical characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang

China: a retrospective, multi-centre case series

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Clinical characteristics of 91 novel coronavirus pneumonia patients in Jingmen First People' s Hospital

Laboratory test analysis of sixty-two COVID-19 patients

Clinical characteristics of 80 patients with COVID-19 in Zhuzhou City

Clinical characteristics, treatment, and prognosis in 89 cases of COVID-2019

Clinical and epidemiological characteristics of 91 children conformed with COVID-19

Clinical characteristic of 90 patients with COVID-19 hospitalized in a Grade-A hospital in Beijing

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study

Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city

Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia

Clinical characteristics and outcomes of 112cardiovascular disease patients infected by 2019-nCoV

Retrospective analysis of COVID-19 patients with different clinical subtypes

Analysis of clinical features of 153 patients with novel coronavirus pneumonia in Chongqing

Clinical features of 30 cases with novel coronavirus pneumonia

Clinical analysis of risk factors for severe patients with novel coronavirus pneumonia

Clinical characteristics of 55 hospitalized patients with COVID-19 in Wuhan

An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19

Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19

A study of laboratory confirmed cases between laboratory indexes and clinical classification of 342 cases with Corona Virus Disease

Analysis of clinical features of 11 death cases caused by COVID-19

COVID-19 with different severity: a multicenter study of clinical features

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Clinical significance of detecting c-reactive protein, interleukin-6 and procalcitonin in COVID-19

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Clinical characteristics and prognosis in cancer patients with COVID-19: a single center's retrospective study

Clinical features of 69 cases with Coronavirus Disease

Changes and clinical significance of serum IL-2R, IL-6 and TNF-a in elderly patients with COVID-19

Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients

Analysis of thecorrelation between clinical characteristics and disease severity in patients with novel coronavirus pneumonia

National Health and Health Commission of the people's Republic of China. Diagnosis and Treatment of Pneumonia of New Coronavirus Infection (Trial Version 7)

Elevated interleukin-6 and severe COVID-19: a meta-analysis

Association of inflammatory markers with the severity of COVID-19: a meta-analysis

The balance of interleukin (IL)-6, IL-6 soluble IL-6 receptor (sIL-6R), and IL-6 sIL-6R sgp130 complexes allows simultaneous classic and trans-signaling

IL-6 and related cytokines as the critical lynchpins between inflammation and cancer

Interleukin-6 mediates angiotensinogen gene expression during liver regeneration

Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever

C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and metaanalysis

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality